Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo® in Patients with Glioblastoma

NEXT STORY
Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 β/γ at AACR Virtual Annual Meeting 2020
PREV STORY
In Vitro Diagnostics (IVD) Market Worth $87.21 Billion by 2024, Growing at a CAGR of 5.7% – Global Opportunity Analysis and Industry Forecasts by Meticulous Research®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

OKYO Pharma Limited Announces final audited results for the year ended 31 March 2021

author_avatar
NASDAQ Market News

Skylight Health to Acquire US Clinic Group with over 6 Locations, $20 Million in Revenue and $3 Million EBITDA

author_avatar
NASDAQ Market News

New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2019

author_avatar
NASDAQ Market News